Optimizing Ophthalmology GLP-1 Prior Auth with Automation

Navigating the complexities of **ophthalmology GLP-1 prior auth** requires a robust automation strategy to manage both high-volume specialty eye care and the increasing demand for GLP-1 medications.

Revenue cycle leaders and prior authorization teams in health systems with ophthalmology departments face a dual challenge: managing the intricate PA requirements for vision-saving treatments alongside the surging volume of GLP-1 prescriptions. Klivira provides a unified platform to streamline these diverse workflows, ensuring efficiency and compliance across the enterprise.

The Dual Challenge: High-Volume Ophthalmology and GLP-1 PA Burdens

Ophthalmology practices contend with chronic PA cycles for anti-VEGF injections (e.g., Eylea, Lucentis, Vabysmo), premium IOLs, and glaucoma surgeries, often requiring specific AAO Preferred Practice Patterns documentation. Simultaneously, GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound generate significant PA volume across the health system, demanding precise indication classification (T2D vs. obesity) and rigorous step therapy adherence. Klivira addresses both, optimizing resource allocation within your revenue cycle.

Key Prior Authorization Triggers in Ophthalmology

Anti-VEGF intravitreal injections (e.g., Aflibercept, Ranibizumab, Faricimab) for wet AMD, DME, RVO.
Cataract surgery with premium IOL or specific lens technology.
Glaucoma surgical procedures (MIGS, trabeculectomy, tube shunts).
Corneal procedures (DSAEK, DMEK, cross-linking for keratoconus).
Oculoplastic procedures requiring medical necessity (e.g., functional blepharoplasty).
High-volume GLP-1 prescriptions for patients within the health system.

Navigating GLP-1 Prior Auth Complexity for Comprehensive Patient Care

While ophthalmologists typically do not prescribe GLP-1s, their patients often receive these medications from other specialists within the same health system. Klivira's platform integrates across specialties, performing indication classification (T2D vs. obesity), per-payer obesity-coverage routing, and automated step therapy documentation by pulling relevant patient data (BMI, A1C, metformin trial history) from the EMR via FHIR. This ensures a holistic view of patient care and PA status, preventing delays for your ophthalmology patients on these medications.

Klivira's Intelligent Automation for Diverse PA Workflows

Klivira addresses the unique demands of both ophthalmology and GLP-1 prior authorizations. For eye care, our system supports AAO-guideline-aware anti-VEGF re-authorization workflows, biosimilar substitution routing per payer policy, and logic for cosmetic-vs-medical determinations in oculoplastics. For GLP-1s, we provide indication-aware routing, brand-specific PA criteria enforcement, and integrated specialty pharmacy fulfillment. This comprehensive approach streamlines diverse PA categories within a single platform.

EMR and Payer Touchpoints for Streamlined PA

EMR integration (e.g., Epic, Cerner) via SMART on FHIR for clinical data extraction (OCT findings, visual acuity, BMI, A1C).
Automated submission via X12 278, ePA portals, and payer-specific channels.
Policy engine referencing payer-specific criteria for anti-VEGF, premium IOLs, and GLP-1s.
Real-time status updates pushed back to the EMR for visibility.
Integration with specialty pharmacy for post-approval fulfillment of GLP-1s.

Evidence-Grounded PA Adherence and Denial Reduction

Our platform incorporates clinical guideline bodies like the ADA Standards of Care for T2D management and AAO Preferred Practice Patterns for ophthalmology. This ensures that documentation for anti-VEGF injections, premium IOLs, and GLP-1s aligns with established medical necessity criteria. By proactively addressing common denial reasons such as biosimilar substitution issues, prior-treatment response gaps, or missing visual field documentation, Klivira helps reduce rework and accelerate approvals.

Frequently asked questions

How does Klivira handle the chronic re-authorization cycles for anti-VEGF injections in ophthalmology?

Klivira automates the periodic re-authorization process for anti-VEGF injections by leveraging EMR data, including OCT findings and visual acuity, to document ongoing medical necessity and treatment response, aligning with AAO guidelines. This reduces manual effort for high-volume, recurring PAs.

Can Klivira differentiate between T2D and obesity indications for GLP-1 prior authorizations?

Yes, Klivira's policy engine identifies T2D versus obesity indications from EMR diagnosis codes and clinical context. It then applies per-payer obesity benefit status and routes the PA accordingly, a critical step given the varying coverage for anti-obesity medications.

How does Klivira integrate with our existing EMR for both ophthalmology and GLP-1 PA data?

Klivira integrates with major EMRs using SMART on FHIR capabilities. This allows for automated extraction of relevant clinical documentation, such as OCT findings for eye care and BMI/A1C for GLP-1s, streamlining data collection for authorization requests.

What specific GLP-1 drugs does Klivira support for prior authorization automation?

Klivira's platform supports prior authorization for high-volume GLP-1 receptor agonists and dual GIP/GLP-1 agonists, including Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda, applying brand-specific PA criteria for each.

How does Klivira help reduce denials for complex ophthalmology procedures like functional blepharoplasty or premium IOLs?

For procedures like functional blepharoplasty, Klivira ensures proper documentation, such as visual field tests demonstrating field defects and photographs, to establish medical necessity. For premium IOLs, it helps manage the specific payer requirements that differentiate standard from specialty lens technologies.